ENDRA Life Sciences Inc Dossier - Source-backed chat

ENDRA Life Sciences Inc

NDRANASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.30

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.88Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $8.8M

Enterprise Value $7.1M

Shares Outstanding 1.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ENDRA Life Sciences is a pre-revenue medical technology company developing its proprietary Thermo Acoustic Enhanced UltraSound (TAEUS) platform, initially targeting steatotic liver disease (SLD). While recent multi-site clinical validation results demonstrate strong diagnostic accuracy (r=0.90 correlation with MRI-PDFF), the company faces severe financial distress, high cash burn, and Nasdaq delisting risks. The Board's initiation of a strategic alternatives review in March 2026 and a subsequent $3.8 million private placement in May 2026 highlight the transitional and highly speculative nature of the stock, justifying a Hold rating for risk-tolerant investors waiting for a definitive strategic transaction.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$25.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger with Noble Africa fails to close due to regulatory or shareholder hurdles, and the company fails to commercialize its TAEUS technology, leading to cash depletion and eventual delisting from Nasdaq under the strict Discretionary Panel Monitor oversight.

Base CaseCentral scenario

The company successfully leverages its newly raised capital and clinical validation data to secure a strategic partnership, licensing agreement, or acquisition that provides a path to commercialization for the TAEUS Liver device, while resolving its Nasdaq listing compliance issues.

Bull CaseUpside scenario

The proposed merger with Noble Africa successfully closes, transforming the company into a Nasdaq-listed pure-play helium platform (NOBA) backed by Renergen's high-grade Virginia Gas Project, securing $50 million in concurrent financing and driving significant long-term cash flows.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical validation data showing TAEUS Liver device has a 0.90 correlation with gold-standard MRI-PDFF.
Large addressable market with SLD affecting approximately 30% of adults worldwide.
Recent $3.8 million private placement in May 2026 provides near-term working capital to address stockholders' equity requirements.

Key Investment Risks

Pre-revenue status with persistent operating losses and high cash burn.
Severe risk of Nasdaq delisting if stockholders' equity cannot be sustained above the $2.5 million threshold.
High execution and regulatory risk associated with FDA de novo submission and commercial adoption.

Thesis Invalidation Triggers

Failure to regain or maintain Nasdaq listing compliance leading to delisting.
Inability to secure a strategic transaction or partnership through the ongoing strategic review process.
Negative feedback or rejection from the FDA regarding the TAEUS Liver device clinical study design.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.